ClinicalTrials.Veeva

Menu

Post-operative Urinary Retention (POUR) Following Thoracic Surgery

Hackensack Meridian Health logo

Hackensack Meridian Health

Status and phase

Enrolling
Phase 2
Phase 1

Conditions

Urinary Retention

Treatments

Drug: Tamsulosin - 3 days
Drug: Tamsulosin - 1 week

Study type

Interventional

Funder types

Other

Identifiers

NCT03609580
PRO#2017-0687

Details and patient eligibility

About

Inability to urinate a common complication that happens to many patients after a surgery, especially in men over 60 years of age who undergo surgery on their chest. Urinary retention is uncomfortable, increases anxiety, increases hospital length of stay, and leads to more procedures such as putting in a bladder catheter (Foley). This is uncomfortable, and can lead to bleeding, infection, damage to the urethra and/or bladder and bladder spasm. The goal of this study is to attempt to prevent inability to urinate by giving patients a medication called Flomax (Tamusolin) every day beginning a week before surgery. That medication relaxes the prostate. It's approved by the Food and Drug Administration (FDA) to improve urinary flow in those with enlarged prostates. It is also commonly used in patients with bladder problems due to inability to urinate who have required a Foley.

Full description

Post-operative urinary retention (POUR) in older men who undergo a thoracic surgical procedure occurs in a significant proportion of patients (25% at Hackensack University Medical Center in men >60) and is a significant management problem. Typically, this complication needs to be treated with placement of a bladder catheter (foley). In addition to the discomfort of placing a foley in an awake patient, these patients are at a significantly increased risk of a catheter associated urinary tract infection (CAUTI), potential genito-urinary injury during the placement, and bladder muscle damage due to distention.

The goal of this study is to investigate whether the use of Tamusolin could lower the high incidence of POUR in older men undergoing a thoracic surgical procedure.

The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 1 week), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.

Enrollment

127 estimated patients

Sex

Male

Ages

50+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Males

≥50 years old Planned surgical procedure of a minimally invasive thoracic surgical procedure (wedge resection, segmentectomy, lobectomy, pleural biopsy, or pleurodesis) Surgery scheduled more than 3 days from the time of consent

Exclusion criteria

  • Using Flomax already
  • Allergy to Flomax or sulfa drugs
  • Current use of alpha blockers or alpha agonists
  • Resting systolic blood pressure <100
  • Orthostatic hypotension of >20mm Hg (millimeters of mercury) Systolic and/or 10mm Hg diastolic pressure from sitting to standing (after 2 minutes of standing) as measured at the time of consent
  • Known diagnosis of congestive heart failure and valvular heart disease
  • History of prostate surgery (prostatectomy, trans-urethral resection)

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

127 participants in 2 patient groups

1 week Pre-operative Tamsulosin administration
Experimental group
Treatment:
Drug: Tamsulosin - 1 week
3 days Pre-operative Tamsulosin administration
Experimental group
Treatment:
Drug: Tamsulosin - 3 days

Trial contacts and locations

1

Loading...

Central trial contact

Daniel Mansour, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems